Tag Archives: UK

Bid to Improve Access to Medicines in Scotland

Access to new medicines: A new, improved, approach in Scotland By Leela Barham A major Inquiry into access to new medicines across Scotland by the Scottish Health and Sport Committee has come to an end. The Scottish Government has responded, and announced changes to how Scotland makes decisions on what new medicines to use across […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed | Also tagged , , | Leave a comment

Big Pharma Welcomes Extension to England's Cancer Drug Fund, Critics Unconvinced

The Cancer Drugs Fund: Extension to 2016 By Leela Barham The Cancer Drugs Fund (CDF) in England covers the cost of cancer treatments either when the National Institute for Health and Care Excellence (NICE) has said ‘no’, or hasn’t yet come to a view.  It started with £50 million and is now £200million a year. […]
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

The Curious Case Of AstraZeneca v. ACE

by Mike Kelly and Andrew Dupre Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. From 2003 to 2012, AstraZeneca Plc was locked in one of the largest mass tort litigations in the United States, defending its blockbuster second generation atypical antipsychotic product Seroquel from allegations of failure-to-warn of […]
Posted in compliance, Europe, Guest Blog, leadership, Legal, Marketing, Regulatory, Safety, Sales, Strategy | Also tagged , , , , , , , | Leave a comment

Orphan Drug Adoption: the More Regulation, the Better

New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks. In his study, ‘The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries,’ John Matthews, Associate Director of […]
Posted in Europe, Global, Market Access, Orphan Drugs, pricing, Regulatory | Also tagged , , , , , | Leave a comment

UK: NICE's Looming Value-Based Pricing Challenges

NICE role in VBP The National Institute for Health and Care Excellence (NICE) will have a vital role in the post 2014 value based pricing (VBP) world.  The Department of Health (DH) who still act as the sponsor organization for the agency, has set out in more detail just what value assessment by NICE will […]
Posted in Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment
  • Categories

  • Meta